R&D AI can help us build a new, more precise, antibiotic pipelin... AI has begun to influence early-stage antibiotic discovery by identifying novel antibacterial compounds that are difficult to uncover traditionally.
News AI start-up Profluent nabs Lilly as first big pharma partner AI start-up Profluent has signed a major alliance with pharma group Eli Lilly, worth up to $2.25bn, that will focus on gene-editing therapies.
News MSD cuts $1bn AI tool deal with Google Cloud MSD has agreed a deal with Google Cloud that will put the tech giant's AI tools in the hands of its 75,000 employees worldwide.
News Neurology, biomanufacturing start-ups bag UK AI funding The first recipients of the UK government's £500 million Sovereign AI fund have been announced, including two life sciences-focused start-ups.
News OpenAI introduces GPT-Rosalind, its drug discovery AI In this week's second AI model launch for life sciences research, OpenAI has introduced GPT-Rosalind, named after UK scientist Rosalind Franklin.
News Novartis CEO joins board of "responsible" AI firm Anthropic In another signal of the deepening relationship between the pharma and AI sectors, Novartis CEO Vas Narasimhan has joined the board of Anthropic.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.